Journal of Research in Pharmacy, published by Marmara University, serves as a pivotal platform for the dissemination of innovative research in the field of pharmacology and pharmaceutical sciences. With an ISSN of 2630-6344 and an E-ISSN of the same, this journal is dedicated to publishing high-quality research spanning various aspects of pharmacology, toxicology, and pharmaceutics. The journal, categorized in Q3 for both pharmacology (medical) and miscellaneous pharmacology, toxicology, and pharmaceutics in 2023, showcases the ongoing evolution of these disciplines amid growing scientific inquiry. As of now, it ranks #56/80 in general pharmacology, toxicology and pharmaceutics, spotlighting its relevance within the academic community. Although it operates under a traditional access model, the journal is committed to providing researchers, professionals, and students with a comprehensive understanding of contemporary challenges and innovations in pharmacy research. Established in 2019, it continues to foster academic dialogue and contribute significantly to the advancement of pharmacological sciences until at least 2024. For all interested in cutting-edge pharmaceutical research, this journal presents an invaluable resource from its base in Istanbul, Turkey.

Ars Pharmaceutica is a distinguished open-access journal published by UNIV GRANADA, EDITORIAL, that has been at the forefront of pharmaceutical sciences since its establishment. With ISSN 0004-2927 and E-ISSN 2340-9894, this journal aims to disseminate high-quality research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of the field. With a historical scope that spans from 1980 to 2017, it has played a pivotal role in shaping the discourse surrounding pharmaceutical science and its intersection with the arts and humanities. Although currently ranked within the 13th percentile in Scopus for Pharmaceutical Science and the 11th percentile for History and Philosophy of Science, Ars Pharmaceutica continues to uphold its commitment to academic excellence and innovation. By providing a platform for open-access research, it encourages collaboration and knowledge sharing among researchers, professionals, and students, thus enhancing the broader understanding of pharmaceutical developments and their societal implications.

Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.

DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.

International Journal of Pharmaceutical Investigation, published by INPHARM ASSOC, PHCOG NET, is a premier platform dedicated to advancing the field of pharmaceutical sciences. With the ISSN 2230-973X and E-ISSN 2230-9713, this journal serves as a vital resource for researchers, professionals, and students focused on drug development, formulation, and efficacy. By fostering a rich discourse on innovative pharmaceutical practices and research breakthroughs, the journal plays a critical role in enhancing global health outcomes through groundbreaking scholarly work. The absence of open access allows for selective dissemination of high-quality content, promoting rigorous peer-review processes that uphold academic integrity. Featuring articles that span a diverse range of topics within pharmaceutical sciences, the International Journal of Pharmaceutical Investigation is committed to supporting the ongoing evolution of this dynamic field, making it an essential read for anyone engaged in pharmaceutical research and development.

PHARMACIA is a distinguished open-access journal, published by PENSOFT PUBLISHERS, that has been a pivotal platform for advancing the field of pharmaceutical sciences since 2007. This journal, with ISSN 0428-0296 and E-ISSN 2603-557X, is based in Bulgaria and continues to publish high-quality research and reviews relevant to pharmacy, pharmacology, and toxicology. Recognized in the Q3 category for Pharmaceutical Sciences and Pharmacology (medical), as well as Q2 in Pharmacy according to the latest rankings, PHARMACIA is celebrated for its commitment to fostering knowledge dissemination and innovation in drug development, therapeutic approaches, and pharmacological research. With a Scopus rank of #17 in Pharmacy and recognition in various health professions, the journal attracts contributions from researchers, professionals, and students seeking to impact the pharmaceutical landscape. Its convenient open-access format ensures that articles are readily available to a global audience, encouraging collaboration and advancement in the life sciences.

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

The Egyptian Pharmaceutical Journal, published by Wolters Kluwer Medknow Publications, stands as a vital resource for researchers and practitioners in the fields of pharmaceutical sciences and biotechnology. With an ISSN of 1687-4315 and E-ISSN of 2090-9853, this journal disseminates high-quality, peer-reviewed research that spans a wide array of topics including pharmacology, toxicology, and biochemistry. Despite its emerging status, as reflected in its current Q4 and Q3 quartile rankings across various categories, the journal plays a significant role in contributing to the academic dialogue and promoting innovative findings within the scientific community. Operating from India, the journal is committed to open access principles, ensuring that cutting-edge research is readily available to a global audience. As the journal continues to evolve from its 2019 to 2024 convergence period, it aims to further enhance its impact factor and broaden its scope in the interdisciplinary domains of pharmaceutical sciences. Whether you are a student exploring new frontiers or a seasoned researcher aiming to publish your findings, The Egyptian Pharmaceutical Journal remains a dynamic platform for advancement in your field.

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

The Future Journal of Pharmaceutical Sciences, published by Springer, stands as a vital resource in the realm of pharmaceutical research and innovation. Recognized for its open access initiative since 2015, this journal promotes extensive dissemination of cutting-edge discoveries, fostering collaboration among researchers, industry professionals, and students alike. With an ISSN of 2314-7245 and an E-ISSN of 2314-7253, it aims to bridge the gap between laboratory research and practical applications in the pharmaceutical sciences. Although specific metrics like HIndex and Scopus ranks are currently unavailable, the journal's commitment to high-quality, peer-reviewed content positions it as a promising platform for advancing pharmaceutical science. By engaging with this journal, contributors and readers can participate in the vibrant discourse shaping the future of drug development, therapeutic strategies, and healthcare solutions.